- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
III
Principal Investigator(s)
Myron S. Cohen, MD - University of North Carolina, Chapel Hill
Objective
This study seeks to determine whether initiating ART in ART-naive, HIV infected people can prevent the sexual transmission of HIV among HIV-discordant couples, as well as to demonstrate whether quality of life changes with the initiation of ART. Both opposite and same sex couples will be recruited at study sites in Brazil, India, Malawi, Thailand, the United States, and Zimbabwe for this study. Participating couples will be enrolled for approximately 78 months (6.5 years). Couples will be randomly assigned to one of two arms. HIV infected partners in Arm 1 will begin ART in addition to receiving HIV primary care. HIV infected partners in Arm 2 will receive HIV primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART. All couples will receive HIV counseling and have their urine and blood collected at screening and enrollment, and at selected monthly, quarterly, and yearly intervals. They will be asked to periodically report information about their adherence to the ART regimen.
Note: As of May 10, 2011 per the Data and Safety and Monitoring Board (DSMB) recommendation all HIV-infected participants in Arm 2 who have not already initiated ART will be offered ART as soon as possible.
Prevention Option(s)
Treatment
Study Design
Controlled
Randomized
Arms and Assigned Interventions
Description
Arm 1: Participants will begin ART in addition to receiving HIV primary care.
Mode of Delivery
Tablet
Products
Atazanavir
Didanosine
Efavirenz
Lamivudine
Lopinavir/Ritonavir
Nevirapine
Stavudine
TDF
TDF/FTC (Truvada)
Zidovudine/Lamivudine
ARMs
Experimental
Description
Arm 2: Participants will receive HIV primary care. When the CD4 count in these participants reaches 200 to 250 cells/mm3, drops below 200 cells/mm3, or develops an AIDS-defining illness, they will initiate ART.
Note: Per LoA#5, on the Data and Safety and Monitoring Board (DSMB) recommendation, as of May 10, 2011, all HIV-infected participants in Arm 2 who have not already initiated ART will be offered ART as soon as possible.
Mode of Delivery
Tablet
Products
Atazanavir
Didanosine
Efavirenz
Lamivudine
Lopinavir/Ritonavir
Nevirapine
Stavudine
TDF
TDF/FTC (Truvada)
Zidovudine/Lamivudine
ARMs
Experimental
Official Code
Related Publications
Trial Sponsors
HPTN, NIAID
February 2005
May 2015
Enrollment
3 500
18
Years
Population
Women
Men
Sites
Fenway Health (FH) CRS
Boston, Massachusetts
United States of America
Gaborone Prevention/Treatment Trials CRS
Gaborone
Botswana
Hospital Geral de Nova Iguaçu
Nova Iguacu, Rio de Janeiro
Brazil
Hospital Nossa Senhora da Conceicao
Port Alegre, Rio Grande do Sul
Brazil
Instituto de Pesquisa Clínica Evandro Chagas
Rio de Janeiro
Brazil
HSE-Hospital dos Servidores do Estado
Rio de Janeiro
Brazil
NARI Clinic at NIV
Pune, Maharashtra
India
NARI Pune
Pune, Maharashtra
India
NARI Clinic at Gadikhana Dr. Kotnis Municipal Dispensary
Pune, Maharashtra
India
YRG CARE Medical Ctr., VHS Chennai
Taramani
India
Kemri/Cdc
Kisumu
Kenya
College of Medicine John Hopkins University Clinical Research Site
Blantyre
Malawi
University of North Carolina - Lilongwe
Lilongwe
Malawi
Soweto HPTN CRS
Johannesburg, Gauteng
South Africa
Wits HIV CRS
Johannesburg, Gauteng
South Africa
Chiang Mai University AIDS Prevention
Chiang Mai
Thailand
UZ-Parirenyatwa
Harare
Zimbabwe